{"database": "press", "table": "releases", "rows": [["https://chriscollins.house.gov/media-center/press-releases/congressman-chris-collins-helps-pass-landmark-medical-innovation", "Congressman Chris Collins Helps Pass Landmark Medical Innovation Legislation", "2016-12-01", "2016", "2016-12", "Republican", "House", "NY", "Chris Collins", "C001092", "chriscollins.house.gov", null, null, "legacy", "Congressman Chris Collins (NY-27) today is hailing the passage of the 21st\u00a0Century Cures Act, landmark medical innovation legislation that will directly benefit the lives of Western New Yorkers.\nThe legislation includes $6.3 billion to help accelerate the discovery, development, and delivery of new cures and treatments and provides new funding for the National Institutes of Health (NIH) and Food and Drug Administration (FDA).\nAs a member of the Energy and Commerce Committee and the Health Subcommittee, Congressman Collins was able to play a direct role in the creation of the legislation. He weighed in on key elements of the bill including the inclusion of measures to fight the opioid crisis, which has devastated Western New York, and helped to secure additional funding for the NIH, which will help fund research at places like Roswell Park Cancer Institute.\n\u201cThis bipartisan legislation incentivizes innovation to defeat disease, and most importantly gets cures to the patients who need them most,\u201d said\u00a0Congressman Collins. \u201cThe 21st\u00a0Century Cures Act provides the health care industry with the ability to help the thousands of Western New Yorkers impacted by deadly diseases by creating the life-saving cures those patients need.\u201d\nCongressman Collins specifically authored the following provisions included in the legislation:\u00a0\n Section 3021, which encourages the broader application of innovative clinical trial designs, including the use of Bayesian statistics and adaptive trials, to enhance and accelerate effective clinical trials. These changes to the way the FDA approves clinical trial designs will help unleash new, groundbreaking therapies by allowing researchers to efficiently change their trials to meet the individual responses of their participants.\u00a0\n  Section 3071 will expedite and improve the drug approval process by increasing the number of senior biomedical researchers the FDA is allowed to hire and also making the salary of those individuals more competitive with private industry. This will help ensure that our best and brightest scientists will remain with the FDA to review and approve drug applications, and get cures to patients more quickly.\n  Section 9023, in collaboration with Congressman Joe Courtney, which allows child and adolescent psychiatrists to participate in the National Health Service Corps Loan Repayment Program. This will incentivize these subspecialists to begin their practices in underserved areas, like those in rural Western New York.\n \u201cI am proud to have had a role in crafting this landmark legislation,\u201d continued\u00a0Congressman Collins. \u201cEnsuring medical innovators have the funding and ability to do their jobs is crucial to helping the millions of Americans struggling with incurable diseases. This legislation has the ability to change people\u2019s lives, and I could not be more excited about its passage.\u201d\nThe 21st\u00a0Century Cures Act will:\n Provide $1 billion in grants to states to address the opioid crisis, which is critical to Western New York.\n\t\t\u00a0\n\tAddresses the country\u2019s mental health crisis and help the one out of five adult Americans suffering from mental illness and substance abuse disorders receive the care they need.\n\t\t\u00a0\n\tProvide $4.8 billion to National Institutes of Health, including: $1.4 billion for President Obama\u2019s Precision Medicine Initiative to drive research into the genetic, lifestyle and environmental variations of disease; $1.8 billion for Vice President Biden\u2019s \"Cancer Moonshot\u201d to speed research; and $1.6 billion for the BRAIN initiative to improve our understanding of diseases like Alzheimer's and speed diagnosis and treatment.\n\t\t\u00a0\n\tHelp bring drugs and devices to market more quickly and at less cost by making needed reforms to the FDA, including: expedited review for breakthrough devices, increased patient involvement in the drug approval process, a streamlined review process for combination products that are both a drug and device, and freedom from red tape for software like fitbit or calorie counting apps.\n\t\t\u00a0\n\tProvide $500 million to the Food and Drug Administration.\n The legislation will now move to the Senate, where it will need to pass before heading to President Obama\u2019s desk to be signed into law. It\u2019s expected to be brought to the Senate for a vote before the end of the year.  \n\t\u00a0\n###", 1, "2026-03-30T12:14:52Z", "2026-03-30T12:14:52Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://chriscollins.house.gov/media-center/press-releases/congressman-chris-collins-helps-pass-landmark-medical-innovation"], "units": {}, "query_ms": 0.7458389736711979, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}